Product Name | TET 830 modified/T – helper epitope from tetanus toxoid |
Product Quantity | 5mg |
Catalog Number | LT2290 |
Molecular Weight | 1796.11 |
Formula | C83H134N20O24 |
Sequence | Ala-Gln-Tyr-Ile-Lys-Ala-Asn-Ser-Lys-Phe-Ile-Gly-Ile-Thr-Glu-Leu, AQYIKANSKFIGITEL |
Product Description | A Phase I trial was carried out to assess both the safety and the immunological response of a melanoma vaccine. This vaccine incorporates the HLA-A2-restricted peptide YLEPGPVTA (gp100(280)), with the option of including a modified T-helper epitope sourced from tetanus toxoid, known as AQYIKANSKFIGITEL. AQYIKANSKFIGITEL, also referred to as TET 830 modified T-helper epitope from tetanus toxoid, serves as a universal human tetanus toxin T cell epitope. Its primary function is to induce T-cell activation, making it a valuable helper peptide in various vaccination strategies. |
Scientific Background | TET 830 modified/T – helper epitope from tetanus toxoid is a 16-residue synthetic peptide with the sequence Ala-Gln-Tyr-Ile-Lys-Ala-Asn-Ser-Lys-Phe-Ile-Gly-Ile-Thr-Glu-Leu. The sequence has a relatively high hydrophobic-residue fraction that can influence aqueous solubility and surface adsorption. These sequence-derived properties describe the reagent chemically; no specific receptor, enzyme, pathway, disease association, or biological activity is assigned without product-specific experimental evidence. |
Research Applications | - LC-MS/HPLC analytical method development
- sequence-specific assay controls
|
Experimental Notes | Sequence-derived chemical properties support reagent selection and experimental planning but do not establish biological function. Solubility, aggregation, adsorption, conjugation efficiency, and assay performance should be validated under the intended experimental conditions. |
